Thor Medical ASA (TRMED.OL)

NOK 2.44

(-0.61%)

EBITDA Summary of Thor Medical ASA

  • Thor Medical ASA's latest annual EBITDA in 2023 was -6.82 Million NOK , down -143.23% from previous year.
  • Thor Medical ASA's latest quarterly EBITDA in 2024 Q2 was -6350.00 NOK , down 0.0% from previous quarter.
  • Thor Medical ASA reported an annual EBITDA of 11.2 Million NOK in 2022, up 102.62% from previous year.
  • Thor Medical ASA reported an annual EBITDA of -428.35 Million NOK in 2021, down -6.88% from previous year.
  • Thor Medical ASA reported a quarterly EBITDA of -6350.00 NOK for 2024 Q2, down 0.0% from previous quarter.
  • Thor Medical ASA reported a quarterly EBITDA of -13.25 Thousand NOK for 2023 Q1, down 0.0% from previous quarter.

Annual EBITDA Chart of Thor Medical ASA (2023 - 2020)

Created with Highcharts 11.1.0YearsEBITDA20202020.252020.52020.7520212021.252021.52021.7520222022.252022.52022.752023-500000000 NOK-400000000 NOK-300000000 NOK-200000000 NOK-100000000 NOK0 NOK100000000 NOK

Historical Annual EBITDA of Thor Medical ASA (2023 - 2020)

Year EBITDA EBITDA Growth
2023 -6.82 Million NOK -143.23%
2022 11.2 Million NOK 102.62%
2021 -428.35 Million NOK -6.88%
2020 -400.79 Million NOK 0.0%

Peer EBITDA Comparison of Thor Medical ASA

Name EBITDA EBITDA Difference
Arctic Bioscience AS -37.78 Million NOK 81.926%
Aqua Bio Technology ASA -16.56 Million NOK 58.781%
ArcticZymes Technologies ASA 31.64 Million NOK 121.581%
BerGenBio ASA -191.8 Million NOK 96.44%
Hofseth BioCare ASA -70.6 Million NOK 90.327%
PCI Biotech Holding ASA -22.22 Million NOK 69.269%
Ultimovacs ASA -214.85 Million NOK 96.822%